1
|
Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L. Novel insights into the host cell glycan binding profile of human metapneumovirus. J Virol 2024; 98:e0164123. [PMID: 38690874 PMCID: PMC11237588 DOI: 10.1128/jvi.01641-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 03/28/2024] [Indexed: 05/03/2024] Open
Abstract
Numerous viruses have been found to exploit glycoconjugates expressed on human cells as their initial attachment factor for viral entry and infection. The virus-cell glycointeractome, when characterized, may serve as a template for antiviral drug design. Heparan sulfate proteoglycans extensively decorate the human cell surface and were previously described as a primary receptor for human metapneumovirus (HMPV). After respiratory syncytial virus, HMPV is the second most prevalent respiratory pathogen causing respiratory tract infection in young children. To date, there is neither vaccine nor drug available to prevent or treat HMPV infection. Using a multidisciplinary approach, we report for the first time the glycointeractome of the HMPV fusion (F) protein, a viral surface glycoprotein that is essential for target-cell recognition, attachment, and entry. Our glycan microarray and surface plasmon resonance results suggest that Galβ1-3/4GlcNAc moieties that may be sialylated or fucosylated are readily recognized by HMPV F. The bound motifs are highly similar to the N-linked and O-linked glycans primarily expressed on the human lung epithelium. We demonstrate that the identified glycans have the potential to compete with the cellular receptors used for HMPV entry and consequently block HMPV infection. We found that lacto-N-neotetraose demonstrated the strongest HMPV binding inhibition in a cell infection assay. Our current findings offer an encouraging and novel avenue for the design of anti-HMPV drug candidates using oligosaccharide templates.IMPORTANCEAll cells are decorated with a dense coat of sugars that makes a sugar code. Many respiratory viruses exploit this sugar code by binding to these sugars to cause infection. Human metapneumovirus is a leading cause for acute respiratory tract infections. Despite its medical importance, there is no vaccine or antiviral drug available to prevent or treat human metapneumovirus infection. This study investigates how human metapneumovirus binds to sugars in order to more efficiently infect the human host. We found that human metapneumovirus binds to a diverse range of sugars and demonstrated that these sugars can ultimately block viral infection. Understanding how viruses can take advantage of the sugar code on our cells could identify new intervention and treatment strategies to combat viral disease.
Collapse
Affiliation(s)
| | - Benjamin Bailly
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| | - Patrice Guillon
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| | - Mark von Itzstein
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| | - Larissa Dirr
- Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
| |
Collapse
|
2
|
Lei ZW, Yao J, Liu H, Ma C, Yang W. Synthesis and Bioactivity of Novel Sulfonate Scaffold-Containing Pyrazolecarbamide Derivatives as Antifungal and Antiviral Agents. Front Chem 2022; 10:928842. [PMID: 35815220 PMCID: PMC9257181 DOI: 10.3389/fchem.2022.928842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 05/13/2022] [Indexed: 12/02/2022] Open
Abstract
Novel pyrazolecarbamide derivatives bearing a sulfonate fragment were synthesized to identify potential antifungal and antiviral agents. All the structures of the key intermediates and target compounds were confirmed by nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS). The single-crystal X-ray diffraction of the compound T22 showed that pyrazole carbamide is a sulfonate. The in vitro antifungal activities of the target compounds against Colletotrichum camelliae, Pestalotiopsis theae, Gibberella zeae, and Rhizoctonia solani were evaluated at 50 μg/ml. Among the four pathogens, the target compounds exhibited the highest antifungal activity against Rhizoctonia solani. The compound T24 (EC50 = 0.45 mg/L) had higher antifungal activity than the commercial fungicide hymexazol (EC50 = 10.49 mg/L) against R. solani, almost similar to bixafen (EC50 = 0.25 mg/L). Additionally, the target compounds exhibited protective effects in vivo against TMV. Thus, this study reveals that pyrazolecarbamide derivatives bearing a sulfonate fragment exhibit potential antifungal and antiviral activities.
Collapse
Affiliation(s)
- Zhi-Wei Lei
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, China
- Tea Research Institute, Guizhou Academy of Agricultural Sciences, Guiyang, China
- *Correspondence: Zhi-Wei Lei,
| | - Jianmei Yao
- Tea Research Institute, Guizhou Academy of Agricultural Sciences, Guiyang, China
| | - Huifang Liu
- Tea Research Institute, Guizhou Academy of Agricultural Sciences, Guiyang, China
| | - Chiyu Ma
- Tea Research Institute, Guizhou Academy of Agricultural Sciences, Guiyang, China
| | - Wen Yang
- Tea Research Institute, Guizhou Academy of Agricultural Sciences, Guiyang, China
| |
Collapse
|
3
|
Cui Y, Zhang G, Li Y, Li W, Tanabe G, Osamu M, Xie W. Microwave‐Assisted Synthesis of
d/l‐
Agrimonolide. ASIAN J ORG CHEM 2022. [DOI: 10.1002/ajoc.202100334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Yu‐Ang Cui
- State Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing 210009 P. R. China
| | - Guang‐Yu Zhang
- State Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing 210009 P. R. China
| | - Yun‐Zhi Li
- State Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing 210009 P. R. China
| | - Wei Li
- State Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing 210009 P. R. China
| | - Genzoh Tanabe
- Faculty of Pharmacy Kinki University 3-4-1 Kowakae Higashi-osaka 577-8502 Osaka Japan
| | - Muraoka Osamu
- Faculty of Pharmacy Kinki University 3-4-1 Kowakae Higashi-osaka 577-8502 Osaka Japan
| | - Wei‐Jia Xie
- State Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry School of Pharmacy China Pharmaceutical University Nanjing 210009 P. R. China
| |
Collapse
|
4
|
You Q, Liao M, Feng H, Huang J. Microwave-assisted decarboxylative reactions: advanced strategies for sustainable organic synthesis. Org Biomol Chem 2022; 20:8569-8583. [DOI: 10.1039/d2ob01677j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Recent advances in the microwave-assisted decarboxylative reactions of carboxylic acids and their derivatives, including transition-metal-catalyzed and metal-free approaches, are summarized.
Collapse
Affiliation(s)
- Qingqing You
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
- China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai 201203, China
| | - Mingjie Liao
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
- China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai 201203, China
| | - Huangdi Feng
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China
| | - Junhai Huang
- China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai 201203, China
| |
Collapse
|
5
|
Abstract
Depending on the strain, influenza A virus causes animal, zoonotic, pandemic, or seasonal influenza with varying degrees of severity. Two surface glycoprotein spikes, hemagglutinin (HA) and neuraminidase (NA), are the most important influenza A virus antigens. NA plays an important role in the propagation of influenza virus by removing terminal sialic acid from sialyl decoy receptors and thereby facilitating the release of viruses from traps such as in mucus and on infected cells. Some NA inhibitors have become widely used drugs for treatment of influenza. However, attempts to develop effective and safe NA inhibitors that can be used for treatment of anti-NA drugs-resistant influenza viruses have continued. In this chapter, we describe the following updates on influenza A NA inhibitor development: (i) N-acetylneuraminic acid (Neu5Ac)-based derivatives, (ii) covalent NA inhibitors, (iii) sulfo-sialic acid analogs, (iv) N-acetyl-6-sulfo-β-D-glucosaminide-based inhibitors, (v) inhibitors targeting the 150-loop of group 1 NAs, (vi) conjugation inhibitors, (vii) acylhydrazone derivatives, (viii) monoclonal antibodies, (ix) PVP-I, and (x) natural products. Finally, we provide future perspectives on the next-generation anti-NA drugs.
Collapse
Affiliation(s)
- Nongluk Sriwilaijaroen
- Department of Preclinical Sciences, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
- Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
| | | | - Hiromasa Kiyota
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan
| | - Yasuo Suzuki
- Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
| |
Collapse
|
6
|
Bifunctional Inhibitors of Influenza Virus Neuraminidase: Molecular Design of a Sulfonamide Linker. Int J Mol Sci 2021; 22:ijms222313112. [PMID: 34884917 PMCID: PMC8657994 DOI: 10.3390/ijms222313112] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 11/29/2021] [Accepted: 11/30/2021] [Indexed: 11/17/2022] Open
Abstract
The growing resistance of the influenza virus to widely used competitive neuraminidase inhibitors occupying the active site of the enzyme requires the development of bifunctional compounds that can simultaneously interact with other regulatory sites on the protein surface. When developing such an inhibitor and combining structural fragments that could be located in the sialic acid cavity of the active site and the adjacent 430-cavity, it is necessary to select a suitable linker not only for connecting the fragments, but also to ensure effective interactions with the unique arginine triad Arg118-Arg292-Arg371 of neuraminidase. Using molecular modeling, we have demonstrated the usefulness of the sulfonamide group in the linker design and the potential advantage of this functional group over other isosteric analogues.
Collapse
|
7
|
Bowles WHD, Gloster TM. Sialidase and Sialyltransferase Inhibitors: Targeting Pathogenicity and Disease. Front Mol Biosci 2021; 8:705133. [PMID: 34395532 PMCID: PMC8358268 DOI: 10.3389/fmolb.2021.705133] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 07/12/2021] [Indexed: 12/15/2022] Open
Abstract
Sialidases (SAs) and sialyltransferases (STs), the enzymes responsible for removing and adding sialic acid to other glycans, play essential roles in viruses, bacteria, parasites, and humans. Sialic acid is often the terminal sugar on glycans protruding from the cell surface in humans and is an important component for recognition and cell function. Pathogens have evolved to exploit this and use sialic acid to either “cloak” themselves, ensuring they remain undetected, or as a mechanism to enable release of virus progeny. The development of inhibitors against SAs and STs therefore provides the opportunity to target a range of diseases. Inhibitors targeting viral, bacterial, or parasitic enzymes can directly target their pathogenicity in humans. Excellent examples of this can be found with the anti-influenza drugs Zanamivir (Relenza™, GlaxoSmithKline) and Oseltamivir (Tamiflu™, Roche and Gilead), which have been used in the clinic for over two decades. However, the development of resistance against these drugs means there is an ongoing need for novel potent and specific inhibitors. Humans possess 20 STs and four SAs that play essential roles in cellular function, but have also been implicated in cancer progression, as glycans on many cancer cells are found to be hyper-sialylated. Whilst much remains unknown about how STs function in relation to disease, it is clear that specific inhibitors of them can serve both as tools to gain a better understanding of their activity and form the basis for development of anti-cancer drugs. Here we review the recent developments in the design of SA and ST inhibitors against pathogens and humans.
Collapse
Affiliation(s)
- William H D Bowles
- Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
| | - Tracey M Gloster
- Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
| |
Collapse
|
8
|
Al‐Zoubi RM, Al‐Jammal WK, McDonald R. Microwave‐Assisted/Pd‐Catalyzed Domino Synthesis of 2,3,4‐Triiodoanisole from 3‐Anisic Acid: A Superior Substrate for Regioselective Synthesis of 2,3‐Diiodobiphenyls. ChemistrySelect 2020. [DOI: 10.1002/slct.202000164] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Raed M. Al‐Zoubi
- Department of ChemistryJordan University of Science and Technology, P.O.Box 3030 Irbid 22110 Jordan
| | - Walid K. Al‐Jammal
- Department of ChemistryJordan University of Science and Technology, P.O.Box 3030 Irbid 22110 Jordan
| | - Robert McDonald
- Department of Chemistry, Gunning-Lemieux Chemistry CentreUniversity of Alberta, Edmonton Alberta T6G2G2 Canada
| |
Collapse
|
9
|
Shie JJ, Fang JM. Development of effective anti-influenza drugs: congeners and conjugates - a review. J Biomed Sci 2019; 26:84. [PMID: 31640786 PMCID: PMC6806523 DOI: 10.1186/s12929-019-0567-0] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 09/16/2019] [Indexed: 12/20/2022] Open
Abstract
Influenza is a long-standing health problem. For treatment of seasonal flu and possible pandemic infections, there is a need to develop new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses, including the resistant strains. Relenza™ (zanamivir), Tamiflu™ (the phosphate salt of oseltamivir), Inavir™ (laninamivir octanoate) and Rapivab™ (peramivir) are four anti-influenza drugs targeting the viral neuraminidases (NAs). However, some problems of these drugs should be resolved, such as oral availability, drug resistance and the induced cytokine storm. Two possible strategies have been applied to tackle these problems by devising congeners and conjugates. In this review, congeners are the related compounds having comparable chemical structures and biological functions, whereas conjugate refers to a compound having two bioactive entities joined by a covalent bond. The rational design of NA inhibitors is based on the mechanism of the enzymatic hydrolysis of the sialic acid (Neu5Ac)-terminated glycoprotein. To improve binding affinity and lipophilicity of the existing NA inhibitors, several methods are utilized, including conversion of carboxylic acid to ester prodrug, conversion of guanidine to acylguanidine, substitution of carboxylic acid with bioisostere, and modification of glycerol side chain. Alternatively, conjugating NA inhibitors with other therapeutic entity provides a synergistic anti-influenza activity; for example, to kill the existing viruses and suppress the cytokines caused by cross-species infection.
Collapse
Affiliation(s)
- Jiun-Jie Shie
- Institute of Chemistry, Academia Sinica, Taipei, 115, Taiwan
| | - Jim-Min Fang
- Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan. .,The Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan.
| |
Collapse
|
10
|
Hadházi Á, Li L, Bailly B, Maggioni A, Martin G, Dirr L, Dyason JC, Thomson RJ, Gao GF, Borbás A, Ve T, Pascolutti M, von Itzstein M. A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity. ChemMedChem 2018; 13:785-789. [DOI: 10.1002/cmdc.201800092] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Indexed: 01/01/2023]
Affiliation(s)
- Ádám Hadházi
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
- Department of Pharmaceutical Chemistry; University of Debrecen; 4032 Debrecen Hungary
| | - Linghui Li
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
- University of Chinese Academy of Sciences; Beijing 101408 China
| | - Benjamin Bailly
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Andrea Maggioni
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Gael Martin
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Larissa Dirr
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Jeffrey C. Dyason
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Robin J. Thomson
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - George F. Gao
- Savaid Medical School; University of Chinese Academy of Sciences; Beijing 101408 China
| | - Anikó Borbás
- Department of Pharmaceutical Chemistry; University of Debrecen; 4032 Debrecen Hungary
| | - Thomas Ve
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Mauro Pascolutti
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| | - Mark von Itzstein
- Institute for Glycomics, Gold Coast Campus; Griffith University; Queensland 4222 Australia
| |
Collapse
|